88 Results for "

vancomycin

" in MedChemExpress (MCE) Product Catalog:
Products (88)

88 Results for "vancomycin" in MCE Product Catalog:

Cat. No.: HY-182798
Research Areas:  

Infection

Antibacterial agent 337 is an antibacterial agent. Antibacterial agent 337 specifically interacts with PG in bacterial cell membranes, triggering membrane disruption, membrane depolarization, increased permeability, cytoplasmic leakage, ROS accumulation and rapid bacterial death. Antibacterial agent 337 inhibits biofilm formation and disrupts mature biofilms. Antibacterial agent 337 exhibits potent in vivo antibacterial efficacy in a mouse model of Staphylococcus aureus skin abscess. Antibacterial agent 337 can be used in studies of Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus infections, vancomycin-resistant Enterococcus faecalis infections and bacterial biofilm infections .
loading...
    loading...
Cat. No.: HY-N21929
CAS No.: 136660-70-3
Target:  

Bacterial

Plusbacin A3 is a cyclic lipodepsipeptide isolated from Pseudomonas sp. PB-6250 that inhibits bacterial cell wall biosynthesis and disrupts membrane integrity. Plusbacin A3 binds lipid intermediates, blocking transglycosylation and lipid intermediate formation in peptidoglycan synthesis. Plusbacin A3 inhibits teichoic acid biosynthesis. Plusbacin A3 exhibits activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci, with low susceptibility to resistance, and is inactive against Gram-negative bacteria. Plusbacin A3 can be used in research on bacterial infections .
loading...
    loading...
Cat. No.: HY-P11085A
Target:  

Bacterial

Research Areas:  

Infection

WLBU2 acetate is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 acetate exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 acetate prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 acetate can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .
loading...
    loading...
Cat. No.: HY-69174
CAS No.: 228862-97-3
1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.
loading...
    loading...
Cat. No.: HY-116880
CAS No.: 2092352-48-0
Research Areas:  

Infection

DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC90: 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin (HY-17580), Metronidazole (HY-B0318), and Vancomycin (HY-B0671), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies .
loading...
    loading...
Cat. No.: HY-L110
100 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 100 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cat. No.: HY-187563
Research Areas:  

Infection

RNP-11 is a selective COX-2 inhibitor with an IC50 of 42.85 μg/mL against human COX-2, and also acts as a bactericide and anti-inflammatory agent. RNP-11 inhibits the production of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β, disrupts bacterial cell membranes and induces bacterial cell death. RNP-11 exhibits activity against strains of Staphylococcus and Enterococcus, including Methicillin (HY-121544)-resistant Staphylococcus aureus and Vancomycin (HY-B0671)-resistant Enterococcus faecium. RNP-11 reduces the load of Staphylococcus aureus, exerting dual effects of pathogen clearance and inflammatory response alleviation in a mouse skin infection model,. RNP-11 can be used in research related to infections caused by Staphylococcus, Staphylococcus aureus and Enterococcus faecium .
loading...
    loading...
Cat. No.: HY-P11615
Target:  

Bacterial

Research Areas:  

Infection

FuK is a WK2-analog antimicrobial peptide modified with fluorinated unnatural amino acids. FuK has an LD50 of 72.34 mg/kg in mice, shows no hemolytic activity, with high stability against trypsin, chymotrypsin, and saline environments. FuK exerts bactericidal effects by enhancing the permeability of bacterial outer membranes, inducing depolarization of cytoplasmic membranes, and disrupting membrane potential balance against bacterias such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and MRSA. FuK exhibits synergistic antimicrobial activity with polymyxin B (HY-149179), vancomycin (HY-B0671), and ciprofloxacin (HY-B0356), and also inhibits Ciprofloxacin-induced bacterial drug resistance. FuK has in vivo safety, effectively reduces bacterial load and inflammatory cell infiltration in a mouse MRSA model, and promotes collagen fiber formation in skin wounds .
loading...
    loading...